TY - JOUR
T1 - Venous thromboembolism at time of diagnosis of ovarian cancer
T2 - Survival differs in symptomatic and asymptomatic cases
AU - Heath, Owen Mortimer
AU - Van Beekhuizen, Heleen J.
AU - Nama, Vivek
AU - Kolomainen, Desiree
AU - Nobbenhuis, Marielle A.E.
AU - Ind, Thomas E.J.
AU - Sohaib, Syed A.
AU - Lofts, Fiona J.
AU - Heenan, Sue
AU - Gore, Martin
AU - Banerjee, Susana
AU - Kaye, Stan B.
AU - Barton, Desmond P.J.
N1 - Publisher Copyright:
© 2015 Elsevier Ltd. All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Objectives To determine the impact on survival of symptomatic and asymptomatic venous thromboembolism (VTE) at time of diagnosis of primary ovarian malignancy. Materials and methods The clinical records of 397 consecutive cases of primary ovarian malignancy were studied. Clinical, pathological and survival data were obtained. Results and conclusions Of 397 cases, 19 (4.8%) were found to have VTE at diagnosis, of which 63.2% (n = 12) were asymptomatic. VTE was significantly associated with reduced overall median survival (28 vs. 45 months, p = 0.004). Decreased survival was associated with symptomatic VTE compared to patients with asymptomatic VTE (21 vs. 36 months, p = 0.02) whose survival was similar to that of patients without VTE. Decreased survival remained significant in symptomatic patients after controlling for stage of disease at diagnosis, cytoreductive status and adjuvant chemotherapy use. Overall these data suggest for the first time that symptomatic but not asymptomatic VTE prior to primary treatment of ovarian cancer is an independent adverse prognostic factor.
AB - Objectives To determine the impact on survival of symptomatic and asymptomatic venous thromboembolism (VTE) at time of diagnosis of primary ovarian malignancy. Materials and methods The clinical records of 397 consecutive cases of primary ovarian malignancy were studied. Clinical, pathological and survival data were obtained. Results and conclusions Of 397 cases, 19 (4.8%) were found to have VTE at diagnosis, of which 63.2% (n = 12) were asymptomatic. VTE was significantly associated with reduced overall median survival (28 vs. 45 months, p = 0.004). Decreased survival was associated with symptomatic VTE compared to patients with asymptomatic VTE (21 vs. 36 months, p = 0.02) whose survival was similar to that of patients without VTE. Decreased survival remained significant in symptomatic patients after controlling for stage of disease at diagnosis, cytoreductive status and adjuvant chemotherapy use. Overall these data suggest for the first time that symptomatic but not asymptomatic VTE prior to primary treatment of ovarian cancer is an independent adverse prognostic factor.
UR - http://www.scopus.com/inward/record.url?scp=84952638881&partnerID=8YFLogxK
U2 - 10.1016/j.thromres.2015.11.030
DO - 10.1016/j.thromres.2015.11.030
M3 - Article
C2 - 26653367
AN - SCOPUS:84952638881
SN - 0049-3848
VL - 137
SP - 30
EP - 35
JO - Thrombosis Research
JF - Thrombosis Research
ER -
